What certifications does the product have?

The product is certified with ISO.

Can I get custom packaging or formulation?

Yes, we offer OEM and ODM services with 20 R&D engineers to support customization.

Feed Additives 80% Vitamin C Soluble Powder

Name: Feed Additives 80% Vitamin C Soluble Powder
Brand: Henan Muxiang Biological Co., Ltd.
SKU: 1973384762

Henan, ChinaHenan Muxiang Biological Co., Ltd.

US$0.65-0.76

2,000 Bags

Sample price:US$1.00/piece.Request sample

Product profile

Customization

Available

Certification

ISO

Shape

Powder

Model NO.

powder

Type

Vitamin

Function

Nutrition Enhancer

Transport Package

25kg/Carton or 25kg/Dump

Specification

100g/bag

Trademark

MOOSUN

Origin

China

HS Code

2309901000

Production Capacity

50t/Month

Key features

High Purity Content: Contains 800mg Vitamin C per gram with medical grade raw materials and low impurities.

Heat Stress Relief: Specifically designed to resist heat stress in poultry and pigs during hot summer weather.

Enhanced Recovery: Aids in disease treatment by enhancing drug efficacy and accelerating recovery processes.

High Stability: Advantageous production process ensures high stability and resistance to oxidation failure.

Versatile Application: Suitable for poultry and pigs of all ages; can be added to feed or water.

Customization Support: ODM and OEM services available with 20 R&D engineers for tailored solutions.

Company profile

Henan Muxiang Biological Co., Ltd.

Henan, China

CertifiedBusiness Type: Manufacturer/Factory & Trading Company CertifiedR&D Capacity: ODM Service Available & OEM Service AvailableExport Year: 2016-02-01 CertifiedNearest Port: Shanghai Port, Qingdao PortAverage Response Time: ≤10.68h CertifiedTerms of Payment: LC, T/T, D/P, etc.

AI-Powered supplier vetting

SummaryHenan Muxiang Biological Co., Ltd. is a China-based limited-company factory established in 2004, with 360 employees and operations in veterinary pharmaceuticals and animal-health products. The supplier reports seven pharmaceutical production lines, eight vaccine production lines, first-class production and inspection equipment, GMP management, ISO9001:2015 certification, and ISO/CNAS laboratory certification. Its R&D resources include more than 40 core personnel, over 30 of whom hold doctoral or master's degrees, while 21–30 quality-control staff are reported. The company exports to multiple global regions, has self-operated import and export rights, and states a one-month order-fulfillment period in both peak and off-peak seasons. Evidence supports capabilities in certification, innovation, production, and international operations. However, the provided information does not sufficiently establish after-sales service performance, financial credibility, customization execution, or specific customer cases.

Supplier typeThe supplier is identified as a limited company and a factory in the manufacturing industry, with its operating location in Henan, China. This indicates a direct manufacturing entity rather than only a trading or intermediary business.

CertificationsThe supplier reports a systematic GMP management system, ISO/CNAS laboratory international certification, and an ISO9001:2015 certificate. These stated certifications and quality systems provide explicit evidence of formal quality-management capability.

R&D capabilityThe supplier reports more than 40 core R&D personnel, including over 30 doctors or master's degree graduates, 20 years of preparation-technology experience among R&D engineers, and advanced R&D platforms such as a National Enterprise Technology Center, National Postdoctoral Research Station, and Academician Workstation. It also reports improving herbal active-ingredient extraction by more than 30% versus a traditional process, supporting a strong stated innovation profile.

Production capacityThe supplier reports seven pharmaceutical production lines and eight vaccine production lines, first-class production and inspection equipment, six production lines in a separate operational data field, and one-month order fulfillment in both peak and off-peak seasons. Although the line-count figures are not fully consistent across the slices, the evidence clearly supports substantial pharmaceutical and vaccine manufacturing capability.